Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2023 Feb 15:14:1140373.
doi: 10.3389/fimmu.2023.1140373. eCollection 2023.

Interleukin-32 as a biomarker in rheumatic diseases: A narrative review

Oh Chan Kwon  1 , Min-Chan Park  1 , Yong-Gil Kim  2   3
Affiliations
Review

Interleukin-32 as a biomarker in rheumatic diseases: A narrative review

Oh Chan Kwon et al. Front Immunol. .

Abstract

Interleukin-32 (IL-32) is an important cytokine involved in the innate and adaptive immune responses. The role of IL-32 has been studied in the context of various diseases. A growing body of research has investigated the role of IL-32 in rheumatic diseases including inflammatory arthritides (rheumatoid arthritis, ankylosing spondylitis, and psoriatic arthritis) and connective tissue diseases (systemic lupus erythematosus, systemic sclerosis, granulomatosis and polyangiitis, and giant cell arteritis). IL-32 has been shown to play different roles according to the type of rheumatic diseases. Hence, the putative role of IL-32 as a biomarker is also different in each rheumatic disease: IL-32 could serve as a biomarker for disease activity in some diseases, whereas in other diseases it could be a biomarker for certain disease manifestations. In this narrative review, we summarize the associations between IL-32 and various rheumatic diseases and discuss the putative role of IL-32 as a biomarker in each disease.

Keywords: IL-32; biomarker; connective tissue disease; inflammatory arthritis; rheumatic disease.

PubMed Disclaimer

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

References

    1. Dahl CA, Schall RP, He HL, Cairns JS. Identification of a novel gene expressed in activated natural killer cells and T cells. J Immunol (1992) 148(2):597–603. doi: 10.4049/jimmunol.148.2.597 - DOI - PubMed
    1. Kim SH, Han SY, Azam T, Yoon DY, Dinarello CA. Interleukin-32: A cytokine and inducer of TNFalpha. Immunity (2005) 22(1):131–42. doi: 10.1016/j.immuni.2004.12.003 - DOI - PubMed
    1. Shim S, Lee S, Hisham Y, Kim S, Nguyen TT, Taitt AS, et al. . A paradoxical effect of interleukin-32 isoforms on cancer. Front Immunol (2022) 13:837590. doi: 10.3389/fimmu.2022.837590 - DOI - PMC - PubMed
    1. Ribeiro-Dias F, Oliveira IBN. A critical overview of interleukin 32 in leishmaniases. Front Immunol (2022) 13:849340. doi: 10.3389/fimmu.2022.849340 - DOI - PMC - PubMed
    1. Calabrese F, Baraldo S, Bazzan E, Lunardi F, Rea F, Maestrelli P, et al. . IL-32, a novel proinflammatory cytokine in chronic obstructive pulmonary disease. Am J Respir Crit Care Med (2008) 178(9):894–901. doi: 10.1164/rccm.200804-646OC - DOI - PubMed

Publication types